BVF Inc. IL lifted its position in Infinity Pharmaceuticals Inc. (NASDAQ:INFI) by 24.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,766,508 shares of the biotechnology company’s stock after buying an additional 1,900,400 shares during the quarter. Infinity Pharmaceuticals comprises approximately 2.4% of BVF Inc. IL’s holdings, making the stock its 14th biggest position. BVF Inc. IL owned approximately 0.19% of Infinity Pharmaceuticals worth $19,826,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently added to or reduced their stakes in the company. Alambic Investment Management L.P. bought a new position in shares of Infinity Pharmaceuticals in the fourth quarter valued at $158,000. Ameriprise Financial Inc. bought a new position in shares of Infinity Pharmaceuticals in the second quarter valued at $130,000. Wells Fargo & Company MN grew its stake in shares of Infinity Pharmaceuticals by 654.7% in the fourth quarter. Wells Fargo & Company MN now owns 105,136 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 91,206 shares in the last quarter. JPMorgan Chase & Co. bought a new position in shares of Infinity Pharmaceuticals in the third quarter valued at $135,000. Finally, Clear Harbor Asset Management LLC bought a new position in shares of Infinity Pharmaceuticals in the fourth quarter valued at $312,000. 50.69% of the stock is owned by institutional investors and hedge funds.
Infinity Pharmaceuticals Inc. (INFI) opened at $2.55 on Friday. Infinity Pharmaceuticals Inc. has a 52 week low of $0.93 and a 52 week high of $3.75. The firm has a market cap of $129.31, a price-to-earnings ratio of -2.24 and a beta of 2.74.
ILLEGAL ACTIVITY WARNING: “BVF Inc. IL Has $19.83 Million Position in Infinity Pharmaceuticals Inc. (INFI)” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3254738/bvf-inc-il-has-19-83-million-position-in-infinity-pharmaceuticals-inc-infi.html.
Infinity Pharmaceuticals Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Want to see what other hedge funds are holding INFI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Infinity Pharmaceuticals Inc. (NASDAQ:INFI).
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.